Skip to content
Screener

Operating Income at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$451.6M+14.5%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$13.85M-18.8%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$58.55M-0.7%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$14.8M+104%
Revvity logo
RevvityRVTY
$75.89M+5.1%
IQVIA logo
IQVIAIQV
$506M0.0%

Segments

By segment

See full
DSA$124.4M+1.3%
Manufacturing$65.61M+444%
RMS$36.28M+1.4%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemThree Months Ended / June 27, 2026Three Months Ended / June 28, 2025Six Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Cost of products sold (excluding amortization of intangible assets)88,69790,192180,956179,200
Selling, general and administrative228,897191,549388,319369,348
Amortization of intangible assets14,58965,38429,934130,648
Operating income119,888100,134239,785174,803
Other income (expense)
Interest income1,0321,0972,0652,501
Interest expense(30,340)(29,967)(57,082)(57,851)
Other (expense) income, net(37,410)154(161,540)(12,057)

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's operating income?
Charles River Laboratories (CRL) reported operating income of $119.89M in Q2 2026.
How has Charles River Laboratories's operating income changed year-over-year?
Charles River Laboratories's operating income increased by 19.7% year-over-year, from $100.13M to $119.89M.
What is the long-term trend for Charles River Laboratories's operating income?
Over 2 years (2021 to 2023), Charles River Laboratories's operating income has grown at a 2.3% compound annual growth rate (CAGR), from $589.86M to $617.26M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Charles River Laboratories's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude